{"id":"chlorphenamine","rwe":[{"pmid":"41732713","year":"2026","title":"The interplay between serotonin syndrome and syndrome of inappropriate antidiuresis: a fatal case of acute hyponatremia during treatment with duloxetine, chlorphenamine, amitriptyline, and L-tryptophan.","finding":"","journal":"Therapeutic advances in psychopharmacology","studyType":"Clinical Study"},{"pmid":"41721172","year":"2026","title":"Risk assessment of a mixture of pharmaceuticals and personal care products (PPCPs) in thermal waters of Kütahya, Türkiye.","finding":"","journal":"Environmental geochemistry and health","studyType":"Clinical Study"},{"pmid":"30000590","year":"2006","title":"Chlorpheniramine.","finding":"","journal":"","studyType":"Clinical Study"},{"pmid":"41547868","year":"2026","title":"Behavioral abnormalities in older patients with chronic renal function decline following administration of compound paracetamol and amantadine hydrochloride capsules.","finding":"","journal":"Journal of medical case reports","studyType":"Clinical Study"},{"pmid":"41466925","year":"2025","title":"Successful Management of Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema With Tranexamic Acid: A Case Report.","finding":"","journal":"Cureus","studyType":"Clinical Study"}],"tags":[{"label":"Histamine-1 Receptor Antagonist","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Histamine H1 receptor","category":"target"},{"label":"HRH1","category":"gene"},{"label":"SLC6A4","category":"gene"},{"label":"HRH4","category":"gene"},{"label":"R06AB04","category":"atc"},{"label":"Oral","category":"route"},{"label":"Aerosol","category":"form"},{"label":"Capsule","category":"form"},{"label":"Active","category":"status"},{"label":"Allergic conjunctivitis","category":"indication"},{"label":"Allergic rhinitis","category":"indication"},{"label":"Common cold","category":"indication"},{"label":"Dermatographic urticaria","category":"indication"},{"label":"Influenza-like symptoms","category":"indication"},{"label":"Itching of skin","category":"indication"},{"label":"Bayer Healthcare Llc","category":"company"},{"label":"Approved 1950s","category":"decade"},{"label":"Anti-Allergic Agents","category":"pharmacology"},{"label":"Antipruritics","category":"pharmacology"},{"label":"Dermatologic Agents","category":"pharmacology"},{"label":"Histamine Agents","category":"pharmacology"},{"label":"Histamine Antagonists","category":"pharmacology"},{"label":"Histamine H1 Antagonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":282.32,"date":"","count":799,"signal":"Drug ineffective","source":"DrugCentral FAERS","actionTaken":"Reported 799 times (LLR=282)"},{"llr":233.36,"date":"","count":13,"signal":"Contraindicated product administered","source":"DrugCentral FAERS","actionTaken":"Reported 13 times (LLR=233)"},{"llr":202.04,"date":"","count":4,"signal":"Pemphigus","source":"DrugCentral FAERS","actionTaken":"Reported 4 times (LLR=202)"},{"llr":190.007,"date":"","count":10,"signal":"Synovitis","source":"DrugCentral FAERS","actionTaken":"Reported 10 times (LLR=190)"},{"llr":169.928,"date":"","count":105,"signal":"Drug intolerance","source":"DrugCentral FAERS","actionTaken":"Reported 105 times (LLR=170)"},{"llr":167.161,"date":"","count":653,"signal":"Sinusitis","source":"DrugCentral FAERS","actionTaken":"Reported 653 times (LLR=167)"},{"llr":165.19,"date":"","count":42,"signal":"Treatment failure","source":"DrugCentral FAERS","actionTaken":"Reported 42 times (LLR=165)"},{"llr":157.495,"date":"","count":30,"signal":"Systemic lupus erythematosus","source":"DrugCentral FAERS","actionTaken":"Reported 30 times (LLR=157)"},{"llr":147.882,"date":"","count":1723,"signal":"Dyspnoea","source":"DrugCentral FAERS","actionTaken":"Reported 1,723 times (LLR=148)"},{"llr":137.293,"date":"","count":25,"signal":"Glossodynia","source":"DrugCentral FAERS","actionTaken":"Reported 25 times (LLR=137)"},{"llr":131.313,"date":"","count":430,"signal":"Chest discomfort","source":"DrugCentral FAERS","actionTaken":"Reported 430 times (LLR=131)"},{"llr":129.491,"date":"","count":443,"signal":"Asthma","source":"DrugCentral FAERS","actionTaken":"Reported 443 times (LLR=129)"},{"llr":126.318,"date":"","count":49,"signal":"Maternal exposure during pregnancy","source":"DrugCentral FAERS","actionTaken":"Reported 49 times (LLR=126)"},{"llr":123.975,"date":"","count":12,"signal":"Pericarditis","source":"DrugCentral FAERS","actionTaken":"Reported 12 times (LLR=124)"},{"llr":120.157,"date":"","count":861,"signal":"Cough","source":"DrugCentral FAERS","actionTaken":"Reported 861 times (LLR=120)"}],"commonSideEffects":[{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Sedation","drugRate":"","severity":"common","organSystem":""},{"effect":"Drowsiness","drugRate":"","severity":"common","organSystem":""},{"effect":"Mental clouding","drugRate":"","severity":"common","organSystem":""},{"effect":"Lethargy","drugRate":"","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"","severity":"common","organSystem":""},{"effect":"Mood changes","drugRate":"","severity":"common","organSystem":""},{"effect":"Constipation","drugRate":"","severity":"common","organSystem":""},{"effect":"Dryness of the pharynx","drugRate":"","severity":"common","organSystem":""},{"effect":"Anxiety","drugRate":"","severity":"common","organSystem":""},{"effect":"Fear","drugRate":"","severity":"common","organSystem":""},{"effect":"Dysphoria","drugRate":"","severity":"common","organSystem":""},{"effect":"Euphoria","drugRate":"","severity":"common","organSystem":""},{"effect":"Impairment of mental and physical performance","drugRate":"","severity":"common","organSystem":""},{"effect":"Psychic dependence","drugRate":"","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"","severity":"common","organSystem":""},{"effect":"Pruritus","drugRate":"","severity":"common","organSystem":""},{"effect":"Tightness of the chest","drugRate":"","severity":"common","organSystem":""},{"effect":"Urinary retention","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Achalasia of esophagus","Acidosis","Acute Thromboembolic Stroke","Acute abdominal pain","Acute erosive gastritis","Acute exacerbation of asthma","Acute hepatitis","Acute nephropathy","Acute pancreatitis","Acute tuberculosis","Agoraphobia","Alcohol intoxication","Alcohol withdrawal delirium","Alcoholism","Anemia","Anemia due to enzyme deficiency","Angle-closure glaucoma","Arterial thrombosis","Arteriosclerotic vascular disease","Asthenia","Atony of colon","Autonomic dysreflexia","Benign intracranial hypertension","Benign prostatic hyperplasia","Bladder outflow obstruction"],"seriousAdverseEvents":[{"effect":"Respiratory depression","drugRate":"","severity":"serious"},{"effect":"Fatal respiratory depression","drugRate":"","severity":"serious"},{"effect":"Death","drugRate":"","severity":"serious"},{"effect":"Ureteral spasm","drugRate":"","severity":"serious"},{"effect":"Spasm of vesical sphincters","drugRate":"","severity":"serious"}]},"trials":[],"aliases":[],"company":"Bayer","patents":[{"source":"FDA Orange Book via DrugCentral","expires":"2032-01-03","territory":"US","patentNumber":"9066942"},{"source":"FDA Orange Book via DrugCentral","expires":"2032-01-03","territory":"US","patentNumber":"9107921"},{"source":"FDA Orange Book via DrugCentral","expires":"2029-03-29","territory":"US","patentNumber":"8062667"},{"source":"FDA Orange Book via DrugCentral","expires":"2027-03-15","territory":"US","patentNumber":"8790700"},{"source":"FDA Orange Book via DrugCentral","expires":"2027-02-28","territory":"US","patentNumber":"7863287"},{"source":"FDA Orange Book via DrugCentral","expires":"2024-05-25","territory":"US","patentNumber":"10238640"}],"pricing":[],"_fixedAt":"2026-03-30T16:45:07.948052","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=chlorphenamine","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:24:51.075744+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T03:24:51.075653+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:24:58.938530+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=chlorphenamine","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:24:59.166947+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL505/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:24:59.914257+00:00"}},"allNames":"tussionex pennkinetic","offLabel":[],"synonyms":["chlorphenamine","chloropheniramine","chlorophenylpyridamine","chloroprophenpyridamine","chlorpheniramine","chlorprophenpyridamine","chlorpheniramine maleate","chlorpheniramine tannate","chlorpheniramine polistirex"],"timeline":[{"date":"1950-08-15","type":"positive","source":"DrugCentral","milestone":"FDA approval (Bayer Healthcare Llc)"}],"aiSummary":"Tussionex Pennkinetic, also known as chlorphenamine, is a small molecule histamine-1 receptor antagonist developed by BAYER HEALTHCARE LLC. It was first approved by the FDA in 1950 for various allergic conditions, including allergic conjunctivitis, rhinitis, and skin itching. As a histamine-1 receptor antagonist, Tussionex Pennkinetic works by blocking the action of histamine at its receptor site, thereby reducing symptoms of allergic reactions. The commercial status of Tussionex Pennkinetic is owned by BAYER HEALTHCARE LLC, and its key safety considerations include its potential for drowsiness and interactions with other medications. Overall, Tussionex Pennkinetic is a well-established medication for the treatment of allergic conditions.","approvals":[{"date":"1950-08-15","orphan":false,"company":"BAYER HEALTHCARE LLC","regulator":"FDA"}],"brandName":"Tussionex Pennkinetic","ecosystem":[{"indication":"Allergic conjunctivitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alcaftadine","slug":"alcaftadine","company":"Allergan"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"}],"globalPrevalence":null},{"indication":"Allergic rhinitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"astemizole","slug":"astemizole","company":""}],"globalPrevalence":null},{"indication":"Common cold","otherDrugs":[{"name":"acetylsalicylic acid","slug":"acetylsalicylic-acid","company":"Endo Pharms"},{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"ammonium chloride","slug":"ammonium-chloride","company":"B Braun"},{"name":"azatadine","slug":"azatadine","company":""}],"globalPrevalence":null},{"indication":"Dermatographic urticaria","otherDrugs":[{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"azatadine","slug":"azatadine","company":""},{"name":"brompheniramine","slug":"brompheniramine","company":""}],"globalPrevalence":null},{"indication":"Influenza-like symptoms","otherDrugs":[{"name":"acetylsalicylic acid","slug":"acetylsalicylic-acid","company":"Endo Pharms"},{"name":"brompheniramine","slug":"brompheniramine","company":""},{"name":"caffeine","slug":"caffeine","company":"Novartis"},{"name":"codeine","slug":"codeine","company":"Ani Pharms"}],"globalPrevalence":null},{"indication":"Itching of skin","otherDrugs":[{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"allantoin","slug":"allantoin","company":""},{"name":"ammonium lactate","slug":"ammonium-lactate","company":"Ranbaxy"},{"name":"antazoline","slug":"antazoline","company":"Novartis"}],"globalPrevalence":null},{"indication":"Nasal congestion","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"ammonium chloride","slug":"ammonium-chloride","company":"B Braun"},{"name":"antazoline","slug":"antazoline","company":"Novartis"}],"globalPrevalence":null},{"indication":"Nasal discharge","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"ammonium chloride","slug":"ammonium-chloride","company":"B Braun"},{"name":"antazoline","slug":"antazoline","company":"Novartis"}],"globalPrevalence":30000000}],"mechanism":{"target":"Histamine H1 receptor","novelty":"First-in-class","targets":[{"gene":"HRH1","source":"DrugCentral","target":"Histamine H1 receptor","protein":"Histamine H1 receptor","isPrimary":true,"activityType":"Ki","activityValue":8.15},{"gene":"SLC6A4","source":"DrugCentral","target":"Sodium-dependent serotonin transporter","protein":"Sodium-dependent serotonin transporter"},{"gene":"HRH4","source":"DrugCentral","target":"Histamine H4 receptor","protein":"Histamine H4 receptor"},{"gene":"SLC6A3","source":"DrugCentral","target":"Sodium-dependent dopamine transporter","protein":"Sodium-dependent dopamine transporter"},{"gene":"KCNH2","source":"DrugCentral","target":"Potassium voltage-gated channel subfamily H member 2","protein":"Potassium voltage-gated channel subfamily H member 2"},{"gene":"SLC6A2","source":"DrugCentral","target":"Sodium-dependent noradrenaline transporter","protein":"Sodium-dependent noradrenaline transporter"},{"gene":"HTR2B","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2B","protein":"5-hydroxytryptamine receptor 2B"},{"gene":"SCN1A","source":"DrugCentral","target":"Sodium channel alpha subunits; brain (Types I, II, III)","protein":"Sodium channel protein type 1 subunit alpha"},{"gene":"SCN2A","source":"DrugCentral","target":"Sodium channel alpha subunits; brain (Types I, II, III)","protein":"Sodium channel protein type 2 subunit alpha"},{"gene":"SCN3A","source":"DrugCentral","target":"Sodium channel alpha subunits; brain (Types I, II, III)","protein":"Sodium channel protein type 3 subunit alpha"}],"moaClass":"Histamine H1 Receptor Antagonists","modality":"Small Molecule","drugClass":"Histamine-1 Receptor Antagonist","explanation":"","oneSentence":"","technicalDetail":"Tussionex Pennkinetic (chlorphenamine) is a competitive antagonist at the histamine H1 receptor, which is a G-protein coupled receptor involved in the mediation of allergic responses. By binding to the H1 receptor, chlorphenamine prevents the action of histamine, thereby reducing symptoms of allergic reactions such as vasodilation, increased vascular permeability, and smooth muscle contraction."},"commercial":{"launchDate":"1950","_launchSource":"DrugCentral (FDA 1950-08-15, BAYER HEALTHCARE LLC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/616","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=chlorphenamine","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=chlorphenamine","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:34:46.393109","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:25:01.583798+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"brompheniramine","drugSlug":"brompheniramine","fdaApproval":"1957-08-23","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"dexchlorpheniramine","drugSlug":"dexchlorpheniramine","fdaApproval":"1981-07-14","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"pheniramine","drugSlug":"pheniramine","fdaApproval":"1994-06-08","relationship":"same-class"},{"drugName":"dexbrompheniramine","drugSlug":"dexbrompheniramine","fdaApproval":"1963-10-18","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"chlorphenamine","indications":{"approved":[{"name":"Allergic conjunctivitis","source":"DrugCentral","snomedId":473460002,"regulator":"FDA"},{"name":"Allergic rhinitis","source":"DrugCentral","snomedId":61582004,"regulator":"FDA"},{"name":"Common cold","source":"DrugCentral","snomedId":82272006,"regulator":"FDA"},{"name":"Dermatographic urticaria","source":"DrugCentral","snomedId":7632005,"regulator":"FDA"},{"name":"Influenza-like symptoms","source":"DrugCentral","snomedId":315642008,"regulator":"FDA"},{"name":"Itching of skin","source":"DrugCentral","snomedId":418363000,"regulator":"FDA"},{"name":"Nasal congestion","source":"DrugCentral","snomedId":68235000,"regulator":"FDA"},{"name":"Nasal discharge","source":"DrugCentral","snomedId":64531003,"regulator":"FDA","usPrevalence":null,"globalPrevalence":30000000,"prevalenceMethod":"curated","prevalenceSource":"Influenza Other Respir Viruses, 2023 (PMID:36824394)"},{"name":"Seasonal allergic rhinitis","source":"DrugCentral","snomedId":367498001,"regulator":"FDA"},{"name":"Sneezing","source":"DrugCentral","snomedId":76067001,"regulator":"FDA","eligibility":"Not specified"},{"name":"Urticaria","source":"DrugCentral","snomedId":126485001,"regulator":"FDA","globalPrevalence":68000000,"prevalenceMethod":"ai-extracted","prevalenceSource":"Allergy, 2020 (PMID:31494963)"},{"name":"Vasomotor rhinitis","source":"DrugCentral","snomedId":8229003,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_fixedFields":["primaryTarget"],"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"brompheniramine","brandName":"brompheniramine","genericName":"brompheniramine","approvalYear":"1957","relationship":"same-class"},{"drugId":"dexchlorpheniramine","brandName":"dexchlorpheniramine","genericName":"dexchlorpheniramine","approvalYear":"1981","relationship":"same-class"},{"drugId":"pheniramine","brandName":"pheniramine","genericName":"pheniramine","approvalYear":"1994","relationship":"same-class"},{"drugId":"dexbrompheniramine","brandName":"dexbrompheniramine","genericName":"dexbrompheniramine","approvalYear":"1963","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03301454","phase":"PHASE2","title":"Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal Cancer","status":"TERMINATED","sponsor":"Centre Oscar Lambret","startDate":"2018-08-20","conditions":["Esophageal Cancer, Squamous Cell"],"enrollment":15,"completionDate":"2022-07-05"},{"nctId":"NCT07233330","phase":"PHASE2","title":"Obinutuzumab in Adult Rituximab-Dependent Nephrotic Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2026-02","conditions":["Nephrotic Syndrome，Idiopathic"],"enrollment":10,"completionDate":"2029-03"},{"nctId":"NCT02604199","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-09","conditions":["Hepatitis B"],"enrollment":58,"completionDate":"2017-01"},{"nctId":"NCT02738008","phase":"PHASE2","title":"Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2016-03","conditions":["Hepatitis B"],"enrollment":12,"completionDate":"2016-12"},{"nctId":"NCT02577029","phase":"PHASE2","title":"Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-12","conditions":["Hepatitis B","Hepatitis D"],"enrollment":79,"completionDate":"2016-12"},{"nctId":"NCT02065336","phase":"PHASE2","title":"A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2014-03","conditions":["Hepatitis B, Chronic"],"enrollment":58,"completionDate":"2017-01"},{"nctId":"NCT02604212","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-11","conditions":["Hepatitis B"],"enrollment":32,"completionDate":"2016-12"},{"nctId":"NCT02797522","phase":"PHASE1","title":"A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2016-06","conditions":["Hepatitis B"],"enrollment":47,"completionDate":"2016-11"},{"nctId":"NCT06907355","phase":"PHASE4","title":"CHAO Tos: Codeina, HederA Helix, LevOdropropizina Para la TOS","status":"COMPLETED","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2025-05-13","conditions":["Upper Resp Tract Infection"],"enrollment":196,"completionDate":"2025-12-01"},{"nctId":"NCT04688736","phase":"PHASE2","title":"Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions.","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2021-01-01","conditions":["Allergic Transfusion Reaction"],"enrollment":6642,"completionDate":"2027-06-30"},{"nctId":"NCT06995274","phase":"NA","title":"Umbilical Cord Blood Therapy in a Child With Eosinophilic Duodenitis and Autism Spectrum Disorder: a Case Study","status":"NOT_YET_RECRUITING","sponsor":"Bundang CHA Hospital","startDate":"2025-06-01","conditions":["Autism Spectrum Disorder","Eosinophilic Gastrointestinal Disorders"],"enrollment":1,"completionDate":"2025-12-31"},{"nctId":"NCT05338099","phase":"PHASE1","title":"Determine the Safety and Dose of EN001 in Patients With Duchenne Muscular Dystrophy(DMD)","status":"COMPLETED","sponsor":"ENCell","startDate":"2022-01-18","conditions":["Duchenne Muscular Dystrophy"],"enrollment":7,"completionDate":"2022-12-28"},{"nctId":"NCT01209455","phase":"NA","title":"Mechanisms of N-acetylcysteine Mediated Vascular Adverse Effects","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2011-01-03","conditions":["Poisoning"],"enrollment":24,"completionDate":"2011-07-15"},{"nctId":"NCT05858216","phase":"EARLY_PHASE1","title":"First-generation OTC Antihistamine Use and Voice Function: A Preliminary Study","status":"COMPLETED","sponsor":"Auburn University","startDate":"2023-06-13","conditions":["Voice Disorder Due to Iatrogenic Factor"],"enrollment":8,"completionDate":"2024-04-23"},{"nctId":"NCT05275933","phase":"PHASE2,PHASE3","title":"Efficacy of TCM Capsules Lian Hua Qing Wen Jiao Nang in Mild COVID-19 Patients","status":"COMPLETED","sponsor":"Singapore Chung Hwa Medical Institution","startDate":"2022-04-05","conditions":["COVID-19"],"enrollment":93,"completionDate":"2023-11-22"},{"nctId":"NCT04790487","phase":"PHASE2,PHASE3","title":"Chlorpheniramine Maleate Nasal Spray for Chronic Rhinitis","status":"WITHDRAWN","sponsor":"Larkin Community Hospital","startDate":"2019-07-30","conditions":["Allergic Rhinitis","Nasal Congestion"],"enrollment":0,"completionDate":"2021-12-30"},{"nctId":"NCT04888741","phase":"PHASE2","title":"Methods of T Cell Depletion Trial (MoTD)","status":"UNKNOWN","sponsor":"University of Birmingham","startDate":"2021-02-22","conditions":["Acute Myeloid Leukemia","Acute Lymphoblastic Leukemia","Chronic Myelomonocytic Leukemia","Myelodysplastic Syndromes","Non Hodgkin Lymphoma","Hodgkin Lymphoma","Multiple Myeloma","Chronic Myelogenous Leukemia","Myelofibrosis"],"enrollment":400,"completionDate":"2026-01"},{"nctId":"NCT05886829","phase":"PHASE2,PHASE3","title":"Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-III","status":"COMPLETED","sponsor":"Dr. Ferrer BioPharma","startDate":"2022-07-27","conditions":["COVID-19","Symptoms and Signs","COVID-19 Pandemic","Coronavirus Disease 2019","Coronavirus Infections"],"enrollment":157,"completionDate":"2023-02-01"},{"nctId":"NCT05449405","phase":"PHASE2,PHASE3","title":"Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-I","status":"COMPLETED","sponsor":"Dr. Ferrer BioPharma","startDate":"2021-12-07","conditions":["COVID-19","Symptoms and Signs","COVID-19 Pandemic","Coronavirus Disease 2019","Coronavirus Infections"],"enrollment":101,"completionDate":"2022-03-11"},{"nctId":"NCT01726452","phase":"PHASE3","title":"NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)","status":"COMPLETED","sponsor":"Cancer Trials Ireland","startDate":"2013-01-24","conditions":["Adenocarcinoma of the Oesophagus","Adenocarcinoma of the Oesophago-gastric Junction","Oesophageal Tumours","Junctional Tumours","Oesophageal Cancer"],"enrollment":377,"completionDate":"2022-08-04"},{"nctId":"NCT05520944","phase":"","title":"Accelerating COVID-19 Clinical Recovery in the Outpatient Setting: Retrospective Analysis","status":"UNKNOWN","sponsor":"Dr. Ferrer BioPharma","startDate":"2021-08-26","conditions":["COVID-19","COVID-19 Pandemic","COVID-19 Respiratory Infection","SARS CoV 2 Infection","SARS-CoV-2 Acute Respiratory Disease"],"enrollment":1000,"completionDate":"2022-10-01"},{"nctId":"NCT05489939","phase":"","title":"Safety and Efficacy of Compound Methyl Salicylate Liniment for Topical Pain: a Multicenter Real-World Study in China","status":"COMPLETED","sponsor":"Xiangya Hospital of Central South University","startDate":"2014-05","conditions":["Pain"],"enrollment":3600,"completionDate":"2015-03"},{"nctId":"NCT03879772","phase":"PHASE3","title":"Dose-Ranging Study of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (C95-161)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1996-03-12","conditions":["Rhinitis, Allergic, Seasonal"],"enrollment":679,"completionDate":"1996-07-01"},{"nctId":"NCT05090449","phase":"PHASE1","title":"Non-interaction Study of Chlorthalidone and Losartan in Fixed Combination, in Healthy Subjects, Under Fasting Conditions","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2019-05-01","conditions":["Healthy"],"enrollment":36,"completionDate":"2020-05-25"},{"nctId":"NCT03583567","phase":"PHASE4","title":"Effect of Anti-histamine in Prevention Systolic Hypotension After Protamine","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2018-09-05","conditions":["Protamine Adverse Reaction"],"enrollment":40,"completionDate":"2019-03-31"},{"nctId":"NCT04937101","phase":"NA","title":"The Safety and Effectiveness of Local Injection of Antihistamines in Treatment of Inflammatory Skin Diseases","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-01-01","conditions":["Inflammatory Skin Disease"],"enrollment":78,"completionDate":"2021-12-30"},{"nctId":"NCT04610502","phase":"PHASE2","title":"Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients","status":"COMPLETED","sponsor":"Caja Costarricense de Seguro Social","startDate":"2020-09-06","conditions":["Covid19"],"enrollment":26,"completionDate":"2020-12-06"},{"nctId":"NCT04622761","phase":"PHASE2","title":"Phase II Study of the Use of Neoadjuvant Cabazitaxel With Hormonal Treatment in Patients Operable Prostate Cancer, Assess the Efficacy and Toxicity of Cabazitaxel, and Explore Potential Predictive and Prognostic Markers of Clinical Outcome","status":"NOT_YET_RECRUITING","sponsor":"The Clatterbridge Cancer Centre NHS Foundation Trust","startDate":"2021-01-15","conditions":["Prostate Cancer"],"enrollment":120,"completionDate":"2026-05-02"},{"nctId":"NCT00837837","phase":"PHASE1","title":"Study Evaluating Chlorpheniramine Maleate Liquid in Children and Adolescents","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2008-12-21","conditions":["Allergic Reactions"],"enrollment":36,"completionDate":"2009-02-02"},{"nctId":"NCT04293081","phase":"NA","title":"Preemptive Chlorepheniramine Maleate Reducing Postoperative Agitation","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2019-01-16","conditions":["Agitated; State, Acute Reaction to Stress"],"enrollment":90,"completionDate":"2019-07-30"},{"nctId":"NCT03940391","phase":"NA","title":"Effect of the Antihistamine Injection to Prevent Paradoxical Reaction During Sedative Endoscopy","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2019-05-01","conditions":["Endoscopy"],"enrollment":220,"completionDate":"2020-04-14"},{"nctId":"NCT03296358","phase":"NA","title":"Adding a Short Burst of Corticosteroid to the Conventional Treatment of H1 Antihistamines in Emergency Department.","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2017-10-01","conditions":["Urticaria","Allergy"],"enrollment":75,"completionDate":"2019-10-31"},{"nctId":"NCT03805035","phase":"NA","title":"Anti-histamines Promote Electroacupuncture Analgesia: Basic and Clinical Research","status":"COMPLETED","sponsor":"China Medical University Hospital","startDate":"2019-01-24","conditions":["Pain"],"enrollment":40,"completionDate":"2019-06-30"},{"nctId":"NCT03332524","phase":"PHASE2","title":"Clinical Trial of the Safety and Efficacy of SP160412 in the Temporary Relief of Mild to Moderate Sunburn","status":"TERMINATED","sponsor":"Sephoris Pharmaceuticals LLC","startDate":"2018-01-15","conditions":["Sunburn"],"enrollment":80,"completionDate":"2019-09-25"},{"nctId":"NCT04101500","phase":"PHASE4","title":"Effect of Compound Sodium Chlorate and Aminophylline Tablets on Chronic Obstructive Pulmonary Disease(COPD).","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2019-04-01","conditions":["Acute Exacerbation of Chronic Obstructive Pulmonary Disease"],"enrollment":200,"completionDate":"2024-12-30"},{"nctId":"NCT03315923","phase":"PHASE2,PHASE3","title":"Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients","status":"COMPLETED","sponsor":"Isfahan University of Medical Sciences","startDate":"2017-12-01","conditions":["Secondary Progressive Multiple Sclerosis"],"enrollment":84,"completionDate":"2019-03-01"},{"nctId":"NCT02033707","phase":"PHASE1","title":"Effects of Hallucinogens and Other Drugs on Mood and Performance","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2014-04","conditions":["Healthy"],"enrollment":20,"completionDate":"2019-02"},{"nctId":"NCT02722083","phase":"PHASE2","title":"Exploratory Study for Allergy Relief Onset","status":"TERMINATED","sponsor":"Bayer","startDate":"2016-05-07","conditions":["Rhinitis, Allergic"],"enrollment":1,"completionDate":"2016-07-13"},{"nctId":"NCT02249676","phase":"PHASE2","title":"Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders","status":"COMPLETED","sponsor":"Tianjin Medical University General Hospital","startDate":"2013-01","conditions":["Devic's Syndrome","Devic's Neuromyelitis Optica","Devic Syndrome","Devic's Disease","Devic Disease"],"enrollment":15,"completionDate":"2014-12-31"},{"nctId":"NCT00853294","phase":"PHASE1","title":"Fasting Study of Chlorpheniramine Polistirex and Hydrocodone Polistirex Capsules and Tussionex® Pennkinetic® Extended Release Oral Suspension","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2003-09","conditions":["Healthy"],"enrollment":42,"completionDate":"2003-09"},{"nctId":"NCT00853190","phase":"PHASE1","title":"Fed Study of Chlorpheniramine Polistirex and Hydrocodone Polistirex Capsules and Tussionex® Pennkinetic® Extended Release Oral Suspension","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2003-09","conditions":["Healthy"],"enrollment":43,"completionDate":"2003-10"},{"nctId":"NCT02246166","phase":"PHASE4","title":"The Effect of Paracetamol, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide and Chlorpheniramine Maleate Tablets Compared to Placebo in Subjects Suffering From the Common Cold or Influenza.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-01","conditions":["Common Cold"],"enrollment":53,"completionDate":"2015-02"},{"nctId":"NCT02735070","phase":"PHASE3","title":"Study Comparing Coristina® D to Resfenol® in the Symptomatic Treatment of Common Cold","status":"UNKNOWN","sponsor":"Brainfarma Industria Química e Farmacêutica S/A","startDate":"2016-09","conditions":["Cold"],"enrollment":366,"completionDate":"2017-03"},{"nctId":"NCT02418013","phase":"PHASE1","title":"Clinical Trial to Evaluate the Potential Efficacy and Safety of Human Umbilical Cord Blood and Plasma","status":"UNKNOWN","sponsor":"Bundang CHA Hospital","startDate":"2015-03","conditions":["Aging"],"enrollment":64,"completionDate":"2017-08"},{"nctId":"NCT01938144","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Two Ibuprofen Combination Products for the Treatment of the Common Cold and Flu in Latin America","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2016-04","conditions":["Common Cold"],"enrollment":0,"completionDate":"2016-11"},{"nctId":"NCT00770562","phase":"PHASE3","title":"A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-07","conditions":["Idiopathic Thrombocytopenic Purpura"],"enrollment":103,"completionDate":"2008-07"},{"nctId":"NCT02082054","phase":"PHASE2","title":"StahistRx Phase 2, Five-arm, Parallel Group, Active vs Active, Double-blind Study","status":"UNKNOWN","sponsor":"Magna Pharmaceuticals, Inc.","startDate":"2014-03","conditions":["Rhinitis, Seasonal, Allergic"],"enrollment":125,"completionDate":"2014-05"},{"nctId":"NCT01008397","phase":"PHASE1","title":"Study of AHIST in Seasonal Allergic Rhinitis Patients","status":"WITHDRAWN","sponsor":"Magna Pharmaceuticals, Inc.","startDate":"2011-04","conditions":["Rhinitis, Allergic, Seasonal"],"enrollment":0,"completionDate":"2011-05"},{"nctId":"NCT02069665","phase":"NA","title":"Effectiveness Study of Integrative Treatment for Pediatric Pneumonia","status":"COMPLETED","sponsor":"Liaoning University of Traditional Chinese Medicine","startDate":"2011-12","conditions":["Pneumonia"],"enrollment":451,"completionDate":"2013-08"},{"nctId":"NCT01902836","phase":"PHASE2","title":"Efficacy Study of Dialyzed Leukocytes Extracts to Treat Paediatric Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"National Polytechnic Institute, Mexico","startDate":"2011-08","conditions":["Childhood Atopic Dermatitis"],"enrollment":58,"completionDate":"2013-01"},{"nctId":"NCT00551122","phase":"PHASE1,PHASE2","title":"Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors","status":"UNKNOWN","sponsor":"University of Southampton","startDate":"2006-11","conditions":["Brain and Central Nervous System Tumors","Extragonadal Germ Cell Tumor","Ovarian Cancer","Testicular Germ Cell Tumor"],"enrollment":23,"completionDate":""},{"nctId":"NCT01710592","phase":"PHASE2","title":"A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer","status":"COMPLETED","sponsor":"Cancer Trials Ireland","startDate":"2007-05","conditions":["Gastro Oesophageal Cancer"],"enrollment":35,"completionDate":""},{"nctId":"NCT01158326","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Oral Solution Resfenol in Reducing Symptoms of Common Cold And Flu","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2010-08","conditions":["Common Cold","Influenza"],"enrollment":216,"completionDate":"2011-11"},{"nctId":"NCT01389518","phase":"PHASE3","title":"Efficacy and Safety of Paracetamol, Chlorpheniramine and Phenylephrine in the Treatment of Common Cold and Flu Syndrome","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2009-05","conditions":["Flu"],"enrollment":146,"completionDate":"2009-11"},{"nctId":"NCT00932256","phase":"PHASE1","title":"Clinical Trial of STAHIST in Seasonal Allergic Rhinitis Patients","status":"COMPLETED","sponsor":"Magna Pharmaceuticals, Inc.","startDate":"2009-10","conditions":["Rhinitis, Allergic, Seasonal"],"enrollment":21,"completionDate":"2010-12"},{"nctId":"NCT00940836","phase":"PHASE3","title":"Efficacy and Safety Assessment of an Anti-Cold Preparation in the Symptomatic Treatment of Common Cold and Flu-Like Syndrome","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2009-06","conditions":["Common Cold","Flu-like Syndrome"],"enrollment":146,"completionDate":""},{"nctId":"NCT00555542","phase":"PHASE2","title":"An Analysis of Peripheral Blood T Cell Subsets on Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2006-07","conditions":["Rheumatoid Arthritis"],"enrollment":10,"completionDate":"2008-05"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Aerosol, Capsule","formulations":[{"form":"AEROSOL, SPRAY","route":"ORAL","productName":"ClorRelief"},{"form":"AEROSOL, SPRAY","route":"ORAL","productName":"ClorRelief KIDs"},{"form":"CAPSULE","route":"ORAL","productName":"999 GANMAOLINGCold"},{"form":"CAPSULE","route":"ORAL","productName":"Antiflu DesCough and Flu"},{"form":"CAPSULE","route":"ORAL","productName":"Colcol-S"},{"form":"CAPSULE","route":"ORAL","productName":"Haben Herb"},{"form":"CAPSULE","route":"ORAL","productName":"Stona-S"},{"form":"CAPSULE","route":"ORAL","productName":"999 COLD REMEDY"},{"form":"CAPSULE","route":"ORAL","productName":"FACOL CLASSIC ONE"},{"form":"CAPSULE, COATED PELLETS","route":"ORAL","productName":"CONTAC GOLD"},{"form":"CAPSULE, DELAYED RELEASE PELLETS","route":"ORAL","productName":"KGSALLERGY SOOTHING"},{"form":"CAPSULE, EXTENDED RELEASE","route":"ORAL","productName":"TUSSICAPS"},{"form":"CAPSULE, EXTENDED RELEASE","route":"ORAL","productName":"TussiCaps"},{"form":"CAPSULE, GELATIN COATED","route":"ORAL","productName":"Rapid Release Multi-Symptom Allergy Relief"},{"form":"CAPSULE, GELATIN COATED","route":"ORAL","productName":"Sanaflu Xtra"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000146218","MMSL":"32347","NDDF":"003391","UNII":"3U6IO1965U","VUID":"4017865","CHEBI":"CHEBI:52010","VANDF":"4017864","INN_ID":"104","RXNORM":"142429","UMLSCUI":"C0008281","chemblId":"CHEMBL505","ChEMBL_ID":"CHEMBL505","KEGG_DRUG":"D00665","DRUGBANK_ID":"DB01114","PUBCHEM_CID":"2725","SNOMEDCT_US":"372914003","IUPHAR_LIGAND_ID":"6976","SECONDARY_CAS_RN":"113-92-8","MESH_DESCRIPTOR_UI":"D002744"},"formularyStatus":[],"originalProduct":{"form":"TABLET, COATED","route":"ORAL","company":"GlaxoSmithKline Consumer Healthcare Holdings (US) LLC","brandName":"ADVIL ALLERGY SINUS","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1950-","companyName":"Bayer","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"22.0 hours","clearance":"2.5 mL/min/kg","bioavailability":"41%","fractionUnbound":"0.7%","volumeOfDistribution":"3.3 L/kg"},"publicationCount":123,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"R06AB04","allCodes":["R06AB04","R06AB54"]},"biosimilarFilings":[],"originalDeveloper":"Bayer Healthcare Llc","recentPublications":[{"date":"2026","pmid":"41732713","title":"The interplay between serotonin syndrome and syndrome of inappropriate antidiuresis: a fatal case of acute hyponatremia during treatment with duloxetine, chlorphenamine, amitriptyline, and L-tryptophan.","journal":"Therapeutic advances in psychopharmacology"},{"date":"2026 Feb 21","pmid":"41721172","title":"Risk assessment of a mixture of pharmaceuticals and personal care products (PPCPs) in thermal waters of Kütahya, Türkiye.","journal":"Environmental geochemistry and health"},{"date":"2006","pmid":"30000590","title":"Chlorpheniramine.","journal":""},{"date":"2026 Jan 17","pmid":"41547868","title":"Behavioral abnormalities in older patients with chronic renal function decline following administration of compound paracetamol and amantadine hydrochloride capsules.","journal":"Journal of medical case reports"},{"date":"2025 Nov","pmid":"41466925","title":"Successful Management of Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema With Tranexamic Acid: A Case Report.","journal":"Cureus"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Bayer","companyId":"bayer","modality":"Small Molecule","firstApprovalDate":"1950","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1950-08-15T00:00:00.000Z","mah":"BAYER HEALTHCARE LLC","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"10238640","territory":"US","patent_type":null,"expiry_date":"2024-05-25T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7863287","territory":"US","patent_type":null,"expiry_date":"2027-02-28T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8790700","territory":"US","patent_type":null,"expiry_date":"2027-03-15T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8062667","territory":"US","patent_type":null,"expiry_date":"2029-03-29T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9107921","territory":"US","patent_type":null,"expiry_date":"2032-01-03T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9066942","territory":"US","patent_type":null,"expiry_date":"2032-01-03T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:25:01.583798+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}